Which SLIT tablets are FDA‑approved in the U.S.?

FDA has approved tablets for timothy/grass pollens (GRASTEK; ORALAIR [mixed grasses]), short ragweed (RAGWITEK), and house dust mite (ODACTRA). See FDA’s SLIT tablets list.

Why must my first SLIT tablet dose be taken at the doctor’s office?

FDA labeling requires supervised first dosing with at least 30 minutes of observation because SLIT tablets carry a boxed warning for anaphylaxis and severe local reactions; prescribers must also provide epinephrine and training.

Are liquid SLIT drops FDA‑approved?

No. There are currently no FDA‑approved SLIT liquid/drop products in the United States; use of drops is off‑label.

Do SLIT tablets or drops treat all allergens?

Tablets target specific allergens defined in their labels (grass, short ragweed, house dust mite). Drops can be mixed to include other allergens, but because they are off‑label, dosing and effectiveness across mixtures vary and remain under investigation.

Will insurance cover SLIT?

Coverage for tablets varies by plan but is often handled like other prescription biologics. Off‑label drops are commonly not covered; check your specific benefits.

What FDA approval means for SLIT in the United States

Short answer: Yes for tablets; no for liquid drops. The U.S. Food and Drug Administration (FDA) has approved several sublingual allergen immunotherapy (SLIT) tablets for specific allergens (grass pollens, short ragweed, and house dust mite). These products are prescription biologics with boxed warnings and precise use instructions in their FDA‑approved labeling. By contrast, liquid SLIT “allergy drops” compounded from injectable extracts remain off‑label in the U.S.; major specialty societies recognize ongoing evidence for drops but emphasize that no drop formulation has FDA approval at this time.

Tablets vs. drops at a glance

Topic	SLIT tablets (FDA‑approved)	SLIT drops (off‑label in U.S.)
FDA status	FDA‑approved allergen extract tablets exist for timothy/grass mixes, short ragweed, and house dust mite; each has product‑specific labeling and age ranges.	No FDA‑approved liquid SLIT formulations; drops use allergen extracts off‑label in the U.S. per specialty society guidance.
First dose	Must be administered under supervision in a healthcare setting with at least 30 minutes of observation.	Not FDA‑labeled; initiation protocols vary by clinician and practice.
Epinephrine	Prescribe and teach use of an auto‑injectable epinephrine device for patients on SLIT tablets per FDA labeling.	Not FDA‑labeled; many clinicians still co‑prescribe epinephrine based on risk assessment.
Where taken after first dose	At home, once daily (per label).	At home; dosing schedules and concentrations vary because no standardized FDA label exists.
Evidence	Multiple large randomized trials per FDA approvals; consistent efficacy and safety profiles across approved tablets.	Evidence base exists but is heterogeneous across allergens, doses, and formulations; effectiveness of mixed‑allergen drop regimens remains uncertain per societies and reviews.
Coverage	Often covered like other prescription biologics (plan‑dependent).	Usually not covered by insurance because drops are off‑label.

Why FDA‑approved tablets have supervised first doses and epinephrine

SLIT tablets carry boxed warnings for anaphylaxis and severe local airway reactions. FDA labeling requires the first dose be given under medical supervision with at least 30 minutes of observation, and prescribers must provide and train patients in the use of auto‑injectable epinephrine for emergencies. These risk‑mitigation steps are part of the drug’s approved use conditions.

What “off‑label” means for SLIT drops in the U.S.

“Off‑label” use is legal medical practice, but it is not the same as FDA approval. For liquid SLIT drops, there is no FDA‑approved product or standardized label—clinicians may compound or direct use of allergen extracts intended for injections. National allergy societies note that while research supports SLIT as a modality, the effectiveness of U.S. drop formulations—especially multi‑allergen mixtures and varied dosing schemes—remains uncertain, and drops are not FDA‑approved.

Evidence snapshot

FDA‑approved tablet products (grass, ragweed, dust‑mite) have demonstrated efficacy and safety in large, placebo‑controlled trials submitted for licensure.
Systematic and narrative reviews report consistent efficacy for tablets; studies of drop formulations show greater heterogeneity in regimen and outcomes.
Specialty society guidance (AAAAI/ACAAI Joint Task Force) explicitly distinguishes FDA‑approved tablets from off‑label drops in the U.S. and provides use considerations.

Practical considerations for patients and clinicians

All candidates should be screened for contraindications listed in tablet labels (e.g., severe/uncontrolled asthma, prior severe systemic or severe local SLIT reactions, history of EoE).
For tablets, plan an in‑office first dose, 30‑minute observation, and epinephrine education.
For drops, discuss off‑label status, evidence uncertainty for multi‑allergen mixtures, and typical lack of insurance coverage in the U.S.
Shared decision‑making should weigh allergen targets, convenience, cost, safety profile, and regulatory status.

References

1) U.S. FDA. Allergen Extract Sublingual Tablets overview (lists approved SLIT tablets).

2) U.S. FDA. ODACTRA (house dust mite) — FDA product page and Package Insert (first dose supervised; prescribe epinephrine).

3) U.S. FDA. GRASTEK (timothy grass) — FDA product page (FDA‑approved SLIT tablet).

4) AAAAI. SLIT for allergic rhinitis — public education page (no FDA‑approved liquid SLIT drops; drops’ effectiveness remains under investigation).

5) PubMed (NIH/NLM). “Clinical aspects of sublingual immunotherapy tablets and drops” (SLIT‑T approved; SLIT‑D off‑label in North America; evidence differences).

6) ACAAI. Immunotherapy with allergy tablets — public education summary (tablets FDA‑approved; allergy drops are off‑label in the U.S.).

Last reviewed: October 22, 2025

FAQ

Which SLIT tablets are FDA‑approved in the U.S.? FDA has approved tablets for timothy/grass pollens (GRASTEK; ORALAIR [mixed grasses]), short ragweed (RAGWITEK), and house dust mite (ODACTRA). See FDA’s SLIT tablets list.
Why must my first SLIT tablet dose be taken at the doctor’s office? FDA labeling requires supervised first dosing with at least 30 minutes of observation, due to a boxed warning for anaphylaxis and severe local reactions; prescribers also must provide epinephrine and training.
Are liquid SLIT drops FDA‑approved? No. There are currently no FDA‑approved SLIT liquid/drop products in the U.S.; use of drops is off‑label.
Do SLIT tablets or drops treat all allergens? Tablets target specific allergens defined in their labels (grass, short ragweed, house dust mite). Drops can be formulated to include other allergens, but because they are off‑label, dosing and effectiveness across mixtures vary and remain under investigation.
Will insurance cover SLIT? Tablet coverage varies by plan but is often handled like other prescription biologics. Off‑label drops are commonly not covered. (Check your plan’s policy.)

Is Sublingual Immunotherapy FDA‑Approved? Tablets vs. Drops Explained